The Role of Asunercept as a Selective CD95L Inhibitor in Cutaneous Melanoma: Rationale and Results from an Enhanced TiRP Model

Krendyukov, A.; Kneisel, N.; Zhu, Jingjing; Merz, C.; Richards, D.; Gieffers, C.; van den Eynde, B.

doi:10.1093/annonc/mdz451.026

The Role of Asunercept as a Selective CD95L Inhibitor in Cutaneous Melanoma: Rationale and Results from an Enhanced TiRP Model

Krendyukov, A.

;

Kneisel, N.

;

Zhu, Jingjing

;

Merz, C.

;

van den Eynde, B.

;et.al.

(2019) ESMO Immuno-Oncology Congress 2019 — Location: Geneva, Switzerland (11.December.2019)

Files

1-s20-S092375342034504X-main.pdf

Open Access
Adobe PDF
68.36 KB

Download

Details

Authors

Krendyukov, A.
Author
Kneisel, N.
Author
Zhu, JingjingUCLouvain
Author
Merz, C.
Author
van den Eynde, B.
Author

Affiliations

UCLouvainSSS/DDUV - Institut de Duve

Citations

APA
Chicago
FWB

Krendyukov, A., Kneisel, N., Zhu, J., Merz, C., Richards, D., Gieffers, C., & van den Eynde, B. (2019). The Role of Asunercept as a Selective CD95L Inhibitor in Cutaneous Melanoma: Rationale and Results from an Enhanced TiRP Model. Annals of Oncology, 30(S11), xi43-xi44. https://doi.org/10.1093/annonc/mdz451.026 (Original work published 2019)